Joseph Hagan Net Worth

The estimated Net Worth of Joseph P Hagan is at least $2.22 Million dollars as of 18 January 2024. Mr. Hagan owns over 14,580 units of Regulus Therapeutics Inc stock worth over $87,952 and over the last 9 years he sold RGLS stock worth over $121,789. In addition, he makes $2,014,280 as President, Chief Executive Officer und Director at Regulus Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hagan RGLS stock SEC Form 4 insiders trading

Joseph has made over 21 trades of the Regulus Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 14,580 units of RGLS stock worth $17,350 on 18 January 2024.

The largest trade he's ever made was buying 219,780 units of Regulus Therapeutics Inc stock on 25 July 2017 worth over $200,000. On average, Joseph trades about 10,627 units every 56 days since 2015. As of 18 January 2024 he still owns at least 57,112 units of Regulus Therapeutics Inc stock.

You can see the complete history of Mr. Hagan stock trades at the bottom of the page.

Joseph Hagan biography

Joseph Patrick Hagan serves as President, Chief Executive Officer, Director of the Company. Mr. Hagan previously served as our Chief Operating Officer, principal financial officer and principal accounting officer from January 2016 to May 2017. From June 2011 through December 2015, Mr. Hagan served as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc. From May 2009 to June 2011, Mr. Hagan served as Orexigen’s Senior Vice President, Corporate Development, Strategy and Communications. From September 1998 to April 2008,

What is the salary of Joseph Hagan?

As the President, Chief Executive Officer und Director of Regulus Therapeutics Inc, the total compensation of Joseph Hagan at Regulus Therapeutics Inc is $2,014,280. There are no executives at Regulus Therapeutics Inc getting paid more.

How old is Joseph Hagan?

Joseph Hagan is 51, he's been the President, Chief Executive Officer und Director of Regulus Therapeutics Inc since 2019. There are 9 older and 4 younger executives at Regulus Therapeutics Inc. The oldest executive at Regulus Therapeutics Inc is David Baltimore, 82, who is the Independent Director.

What's Joseph Hagan's mailing address?

Joseph's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS INC., 4224 CAMPUS POINT COURT #210, SAN DIEGO, CA, 92121.

Insiders trading at Regulus Therapeutics Inc

Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.

What does Regulus Therapeutics Inc do?

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Complete history of Mr. Hagan stock trades at Aurinia Pharmaceuticals Inc, Regulus Therapeutics Inc und Zosano Pharma Corp

Regulus Therapeutics Inc executives and stock owners

Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Hagan,
  President, Chief Executive Officer, Director
• Joseph P. Hagan M.B.A.,
  Pres, CEO & Director
• Christopher Aker,
  Senior Vice President, General Counsel
• Christopher Ray Aker J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Crispina Calsada,
  Chief Financial Officer
• Crispina Calsada,
  Chief Financial Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Pascale Witz,
  Independent Director
• Simos Simeonidis,
  Independent Director
• Hugh Rosen,
  Independent Director
• William Rastetter,
  Independent Director
• Jake Nunn,
  Independent Director
• Kathryn Collier,
  Independent Director
• David Baltimore,
  Independent Director
• Denis Drygin,
  Chief Scientific Officer
• Firuz Shakoori,
  Head of CMC
• Turner Jenkins,
  Sr. Director of Corp. Devel.
• Dr. Denis Drygin Ph.D.,
  Chief Scientific Officer
• Daniel J. Penksa,
  Controller & Principal Accounting Officer
• Jason Raleigh Nunn,
  
• Daniel R. Chevallard,
  Chief Financial Officer
• Paul C Grint,
  President & CEO
• Douglas E Williams,
  Director
• Mark Albert Deeg,
  Chief Medical Officer
• Pharmaceuticals, Inc. Alnylam,
  10% owner
• Mark G Foletta,
  Director
• Timothy Michael Wright,
  Chief R & D Officer
• Alexander J Sarissa Capital...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• David Leslie Szekeres,
  Chief Business Officer & GC
• Paul Edward Walker,
  
• Peter J Barris,
  10% owner
• Anthony A. Jr. Florence,
  
• Scott D Sandell,
  
• David M Mott,
  10% owner
• Mohamad Makhzoumi,
  
• Equity Opportunities V, Llc...,
  
• Ali Behbahani,
  
• Neil W Gibson,
  Chief Scientific Officer
• Pharmaceuticals Incparshall...,
  
• Kleanthis G Xanthopoulos,
  President and CEO
• Pharmaceuticals Inc Ionis,
  10% owner
• Bruce L A Carter,
  Director
• Barry E Greene,
  Director
• Sanofi,
  10% owner
• B Lynne Parshall,
  Director
• Stanley T Crooke,
  Director
• John Maraganore,
  Director
• Garry E Menzel,
  COO & Executive VP, Finance
• Forest Baskett,
  
• Carmen Chang,
  
• Joshua Makower,
  
• Peter W. Sonsini,
  
• Capital Offshore Master Fun...,
  10% owner
• Alice Shih Hou Baltimore Da...,
  
• Alice Shih Hou Huang,
  
• Preston Klassen,
  President & Head of R & D